Overview

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Status:
NOT_YET_RECRUITING

Trial end date:
2029-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.

Phase:

PHASE3

Details

Lead Sponsor:

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.